Can-Fite BioPharma Ltd. Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Cover
- Document And Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Accounting Policies, by Policy (Policies)
Notes Tables
Notes Details

Transactions with Related Parties

Transactions with Related Parties	12 Months Ended
Dec. 31, 2022
Related Party Transactions [Abstract]
TRANSACTIONS WITH RELATED PARTIES	NOTE 15:- TRANSACTIONS WITH RELATED PARTIES The Chairman of the Company’s board of directors is a senior partner in the patent firm which represents the Company in intellectual property and commercial matters (the “Service Provider”). The Service Provider charges the Company for services it renders on an hourly basis. The aggregate amount of these expenses was approximately $218, $241 and $252 in 2022, 2021 and 2020, respectively, which were recorded under research and development expenses within Company’s consolidated statements of comprehensive loss.

Transactions with Related Parties

12 Months Ended

Dec. 31, 2022

NOTE 15:- TRANSACTIONS WITH RELATED PARTIES

The Chairman of the Company’s board of directors is a senior partner in the patent firm which represents the Company in intellectual property and commercial matters (the “Service Provider”). The Service Provider charges the Company for services it renders on an hourly basis. The aggregate amount of these expenses was approximately $218, $241 and $252 in 2022, 2021 and 2020, respectively, which were recorded under research and development expenses within Company’s consolidated statements of comprehensive loss.